The first drug in the company's portfolio is SQ109 for the treatment of multidrug-resistant TB (MDR-TB).
Leading drug OС000459 Therapeutic focus: asthma and other respiratory diseases
MBC-11 is chemically synthesized unique conjugate of two molecules (etidronate and cytarabine) designed for treatment of multiple myeloma, osteosarcoma, as well as metastatic bone lesions. The mechanism of action of this drug is based on the ability of bisphopsphonate part of the molecule to deliver the conjugate to the site of bone destruction (targeted delivery).
Maxwell Biotech Group
Maxwell Biotech Group (MBG) is a development partner and financial resource for biotechnology companies. MBG provides investment capital and access to an established infrastructure for conducting high-quality clinical trials in Russia, and helps enable the rapid and cost-effective achievement of clinical objectives. Our unique business model can add value to our partners’ pipelines and provide a commercialization path to one of the most lucrative emerging markets. MBG relies on an experienced international team of managers and financial and industry experts, with representatives in Boston (USA).
Maxwell Biotech Group currently has 9 biotech companies in its portfolio, which are engaged in the development of 11 innovative clinical stage drugs. Four products are in the registration phase of clinical studies.